The aryl hydrocarbon receptor: a rehabilitated target for therapeutic immune modulation. PMID: 40247142 Polonio CM, McHale KA, Sherr DH, Rubenstein D, Quintana FJ. Nat Rev Drug Discov. 2025 Apr 17. doi: 10.1038/s41573-025-01172-x. Online ahead of print.PMID: 40247142 Review. Phosphoinositide kinases in cancer: from molecular mechanisms to therapeutic opportunities. PMID: 40181165 [READ MORE]
Photo Credit: Burcu Elmas (pexels.com 10051526) Resident memory T cells and cancer. Gavil NV, Cheng K, Masopust D. PMID: 39142275 Immunity. 2024 Aug 13;57(8):1734-1751. doi: 10.1016/j.immuni.2024.06.017.PMID: 39142275 Review. Human life within a narrow range: The lethal ups and downs of type I interferons. Crow YJ, Casanova JL. PMID: 38968338 Sci [READ MORE]
Targeting EGFRvIII and CD47-SIRPα: A New CAR-T Strategy for Glioblastoma Treatment Review contributed by: PhD candidate Eugenio Contreras Castillo (one of the 2024 ICIS-Pfizer Trainee Award Winners for Most Promising Research Presentations at Cytokines 2024), Department of Cell Biology Institute of Cellular Physiology (IFC), National Autonomous University of Mexico (UNAM) [READ MORE]
Photo Credit: Burcu Elmas (pexels.com 10051526) A guide to adaptive immune memory.PMID: 38831162Lam N, Lee Y, Farber DL.Nat Rev Immunol. 2024 Jun 3. doi: 10.1038/s41577-024-01040-6. Online ahead of print.PMID:Â 38831162Â Review. Towards a unifying model for B-cell receptor triggering.PMID: 39256626Degn SE, Tolar P.Nat Rev Immunol. 2024 Sep 10. doi: 10.1038/s41577-024-01073-x. Online ahead [READ MORE]
In the Phase 2 CITYSCAPE trial, Tiragolumab, an anti-TIGIT antibody, demonstrated efficacy when combined with Atezolizumab, an anti-PD-L1, compared to Atezolizumab alone for the treatment of non-small cell lung carcinoma. In mouse models, inhibition of both the TIGIT and PD-1 pathways was shown to synergistically function to reinvigorate T cell [READ MORE]
April 17, 2024 – Reviews of Interest PMID: 37726402 Anti-cytokine autoantibodies: mechanistic insights and disease associations. Cheng A, Holland SM. Nat Rev Immunol. 2024 Mar;24(3):161-177. doi: 10.1038/s41577-023-00933-2. Epub 2023 Sep 19.PMID: 37726402 Review. This review provides a comprehensive overview of the emerging field of anti-cytokine autoantibodies (ACAA), including their pathological [READ MORE]
COVID-19 special: PMID: 36198912 COVID-19 and cellular senescence. Schmitt CA, Tchkonia T, Niedernhofer LJ, Robbins PD, Kirkland JL, Lee S. Nat Rev Immunol. 2022 Oct 5:1-13. doi: 10.1038/s41577-022-00785-2. Online ahead of print.PMID: 36198912 Free PMC article. Review.  PMID: 36631691 Innate immune evasion strategies of SARS-CoV-2. Minkoff JM, tenOever B. Nat Rev Microbiol. [READ MORE]
COVID-19 special: PMID: 36198912 COVID-19 and cellular senescence. Schmitt CA, Tchkonia T, Niedernhofer LJ, Robbins PD, Kirkland JL, Lee S. Nat Rev Immunol. 2022 Oct 5:1-13. doi: 10.1038/s41577-022-00785-2. Online ahead of print.PMID: 36198912 Free PMC article. Review. PMID: 36631691 Innate immune evasion strategies of SARS-CoV-2. Minkoff JM, tenOever B. Nat Rev Microbiol. 2023 [READ MORE]
Reviews of Interest to cytokine biologists. [READ MORE]
Reviews of interest related to COVID-19 and cytokine biology [READ MORE]
International Cytokine & Interferon Society, Copyright 2024 Website Design by Rhema Association Management | Privacy Policy
